Texting for Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03025984|
Recruitment Status : Recruiting
First Posted : January 20, 2017
Last Update Posted : December 24, 2020
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus||Behavioral: Texting||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||250 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Adherence to a Diabetes Care Regimen Following Text Message Intervention in Pregnant Women With Diabetes|
|Study Start Date :||December 2016|
|Estimated Primary Completion Date :||August 31, 2021|
|Estimated Study Completion Date :||February 28, 2022|
Active Comparator: Texting
Patients in the "Texting" group will receive reminders based on their individual disease treatment. A text message shall be sent one day (12 to 36 hours) before appointments to remind about the appointment and with instructions to bring glucose and food records to the appointment. If medication changes are made at the appointment, the patient will receive a text message reminder the day after her appointment to reinforce the regimen. Postpartum patients who had GDM will receive a text message reminder to complete their glucose tolerance test. A reminder will be sent at 2 weeks postpartum followed by a reminder at 6 weeks and 10 weeks postpartum if the testing is not completed.
patient adherence to her recommended care regimen after intervention of a text message reminder and education system
No Intervention: No texting
Patients in the contact control group will be enrolled in the text4baby program with assistance from a healthcare provider. As the study will conclude upon the patient's postpartum visit, she will be offered the option of discontinuing messages, which otherwise would continue through the infant's first year of life.
- compliant diabetes care [ Time Frame: up to 12 months ]Compliant with appointments, maintaining diabetes records, and medications, including glycemic control and pregnancy complications.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03025984
|Contact: Shohreh Jamalabadi-Majidi, DMD, MPHfirstname.lastname@example.org|
|Contact: Katherine Mathews, MD, MPH, MBAemail@example.com|
|United States, Missouri|
|St. Mary's Health Center||Recruiting|
|Saint Louis, Missouri, United States, 63117|
|Study Chair:||Dorothea Mostello, MD||St. Louis University|